SLC5A2 and Hyperinsulinemia: Given the multifaceted mechanisms potentially underlying such clinical benefits of SGLT2 inhibition [42, 43], however, whether improvement of hyperinsulinemia and insulin resistance via SGLT2 inhibition directly affects clinical manifestations and prognosis in patients with HF remains poorly understood.